Steven M. Paul, a director at Rapport Therapeutics, Inc. (RAPP), bought $974,278 of the company's common stock on October 22nd, 2026.
The purchase covered 35,714 shares and arrived in a single Form 4. Every share was reported at $27.28, with no spread between the low and the high of the range. That pattern is consistent with one block rather than a series of smaller fills worked across a session.
A single-price buy leaves less room for interpretation than a staggered program. There is no averaging down and no ladder of bids to read into. The filing shows what was paid and when it was paid, and that is the whole of the record.
On size, the purchase is substantial for an individual director and small against the company itself. Rapport Therapeutics carries a market capitalization of roughly $1.2 billion, so a buy just under $1 million is not the kind of transaction that moves the share count in any visible way. Its interest is in who signed for it, not in its weight on the cap table.
The other side of the ledger is the thinness of the sample. This is one filing from one director, not a cluster of officers and board members acting in the same week. Rapport Therapeutics sits in pharmaceutical preparations, a group where clinical and regulatory outcomes tend to overwhelm anything an ownership change might suggest. A director's purchase tells you about a director's own allocation decision and nothing more than that.
Price context cuts against the buyer so far. The shares were acquired at $27.28 and last traded at $25.33, which puts the position below cost on the latest print. Directors buy on their own timetables, inside open windows, and the mark on any given day says little about the horizon behind the trade. Still, the gap is there and it is worth noting rather than skipping past.
Figures above are drawn from the Form 4 filed with the Securities and Exchange Commission and from our own reconciled transaction tables.
Track every Form 4 filed at Rapport Therapeutics, Inc. (RAPP) → insiderbuying.com/companies/RAPP